Tyler B Tarr

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10277707/publications.pdf

Version: 2024-02-01

		1163117	1474206
9	210	8	9
papers	citations	h-index	g-index
9	9	9	238
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATION
1	Are unreliable release mechanisms conserved from NMJ to CNS?. Trends in Neurosciences, 2013, 36, 14-22.	8.6	43
2	Evaluation of a Novel Calcium Channel Agonist for Therapeutic Potential in Lambert-Eaton Myasthenic Syndrome. Journal of Neuroscience, 2013, 33, 10559-10567.	3.6	40
3	Synaptic Pathophysiology and Treatment of Lambert-Eaton Myasthenic Syndrome. Molecular Neurobiology, 2015, 52, 456-463.	4.0	33
4	Complete reversal of Lambert–Eaton myasthenic syndrome synaptic impairment by the combined use of a K ⁺ channel blocker and a Ca ²⁺ channel agonist. Journal of Physiology, 2014, 592, 3687-3696.	2.9	24
5	Synthesis and Biological Evaluation of a Selective N- and P/Q-Type Calcium Channel Agonist. ACS Medicinal Chemistry Letters, 2012, 3, 985-990.	2.8	23
6	Transmitter release site organization can predict synaptic function at the neuromuscular junction. Journal of Neurophysiology, 2018, 119, 1340-1355.	1.8	17
7	Lambert–Eaton myasthenic syndrome: mouse passiveâ€transfer model illuminates disease pathology and facilitates testing therapeutic leads. Annals of the New York Academy of Sciences, 2018, 1412, 73-81.	3.8	14
8	New calcium channel agonists as potential therapeutics in Lambert–Eaton myasthenic syndrome and other neuromuscular diseases. Annals of the New York Academy of Sciences, 2012, 1275, 85-91.	3.8	12
9	Neuromuscular Active Zone Structure and Function in Healthy and Lambert-Eaton Myasthenic Syndrome States. Biomolecules, 2022, 12, 740.	4.0	4